^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    brusatol

    Company:
    National Institutes of Health, National Cancer Institute - Bethesda
    Drug class:
    NRF2 inhibitor
    11ms
    NRF2 activation in BON‑1 neuroendocrine cancer cells reduces the cytotoxic effects of a novel Ruthenium(II)‑curcumin compound: A pilot study. (PubMed, Oncol Rep)
    To assess the interplay between NRF2 and dysfunctional p53, genetic targeting of p53 showed reduced activation of the NRF2 pathway in response to the lower dose of Ru‑bdcurc, increasing the cell death. These findings identified for the first time a possible dysfunctional p53/NRF2 interplay in BON‑1 cell line that can be a novel key determinant in cell resistance to cytotoxic agents to be evaluated also in GEP‑NEN.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CAT (Catalase)
    |
    TP53 expression
    |
    brusatol